Drug Search Results
More Filters [+]

Levocetirizine

Alternative Names: levocetirizine, xyzal, levocetrizine, xarlin, hgp-1408, hgp1408, hgp 1408
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Levocetirizine is used to relieve the symptoms of hay fever and hives of the skin. It is an antihistamine that works by preventing the effects of a substance called histamine, which is produced by the body. Histamine can cause itching, sneezing, runny nose, and watery eyes. (Sourced from: https://www.mayoclinic.org/drugs-supplements/levocetirizine-oral-route/precautions/drg-20071083?p=1)

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Urticaria | Rhinitis | Rhinitis, Allergic | Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Seasonal | Skin Manifestations

Known Adverse Events: Nasopharyngitis | Pharyngitis | Epistaxis

Company: UCB
Company Location: SMYRNA GA 30080
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Levocetirizine

Countries in Clinic: Unknown Location

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Urticaria

Phase 1: Rhinitis, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TACUS

P3

Active, not recruiting

Urticaria

2020-10-17

CTR20180546

P1

Active, not recruiting

Urticaria|Rhinitis, Allergic

None

Recent News Events